Export 5 results:
Author Title [ Type(Desc)] Year
Filters: Author is Yu, Z.-F.  [Clear All Filters]
Journal Article
Harmatz, P., Ketteridge, D., Giugliani, R., Guffon, N., et al. (2005). Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): Results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylga. Pediatrics, 115(6), e681 - e689.
Harmatz, P., Giugliani, R., Schwartz, I., Guffon, N., et al. (2006). Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-l. Journal of Pediatrics, 148(4), 533 - 533.e.
Harmatz, P., Yu, Z. - F., Giugliani, R., Schwartz, I. V. D., et al. (2010). Enzyme replacement therapy for mucopolysaccharidosis VI: Evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. Journal of Inherited Metabolic Disease, 33(1), 51 - 60.
Decker, C., Yu, Z. - F., Giugliani, R., Schwartz, I. V. D., et al. (2010). Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. Journal of Pediatric Rehabilitation Medicine, 3(2), 89 - 100.
Harmatz, P., Giugliani, R., D. Schwartz, I. V., Guffon, N., et al. (2008). Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Molecular Genetics and Metabolism, 94(4), 469 - 475.

Home | Site Map | Contacts | Credits | Privacy & Cookies | Intranet | Social Networks |


rua alfredo allen, 208, 4200-135 porto - portugal | tel +351 220 408 800 | email: info@ibmc.up.pt | © copyright 2010 ibmc